Victory Capital Management Inc. Acquires 50,057 Shares of Disc Medicine, Inc. (NASDAQ:IRON)

Victory Capital Management Inc. boosted its position in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 36.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 187,580 shares of the company's stock after acquiring an additional 50,057 shares during the period. Victory Capital Management Inc. owned 0.78% of Disc Medicine worth $10,835,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of IRON. Adage Capital Partners GP L.L.C. increased its position in Disc Medicine by 12.5% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,308,405 shares of the company's stock valued at $61,469,000 after purchasing an additional 145,781 shares during the period. Vanguard Group Inc. raised its stake in Disc Medicine by 18.9% in the third quarter. Vanguard Group Inc. now owns 665,452 shares of the company's stock worth $31,263,000 after buying an additional 105,685 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Disc Medicine by 309.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 84,200 shares of the company's stock worth $3,956,000 after buying an additional 63,644 shares during the period. Rafferty Asset Management LLC bought a new stake in Disc Medicine during the 3rd quarter valued at approximately $2,966,000. Finally, Invesco Ltd. boosted its position in Disc Medicine by 45.7% during the 3rd quarter. Invesco Ltd. now owns 161,213 shares of the company's stock valued at $7,574,000 after acquiring an additional 50,581 shares in the last quarter. Hedge funds and other institutional investors own 83.70% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Raymond James raised their target price on Disc Medicine from $40.00 to $43.00 and gave the company an "outperform" rating in a research note on Friday. Wedbush restated an "outperform" rating and set a $43.00 target price (down previously from $84.00) on shares of Disc Medicine in a report on Monday, April 1st. Stifel Nicolaus increased their price target on shares of Disc Medicine from $71.00 to $73.00 and gave the stock a "buy" rating in a research note on Monday, April 8th. HC Wainwright reissued a "buy" rating and set a $70.00 price objective on shares of Disc Medicine in a research note on Friday. Finally, Morgan Stanley cut their price objective on shares of Disc Medicine from $75.00 to $40.00 and set an "equal weight" rating on the stock in a report on Tuesday, April 2nd. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $57.71.

Insider Buying and Selling

In related news, Director William Richard White sold 2,560 shares of the stock in a transaction dated Thursday, April 11th. The shares were sold at an average price of $31.80, for a total value of $81,408.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.24% of the stock is currently owned by insiders.

Disc Medicine Stock Up 2.1 %

IRON traded up $0.65 during mid-day trading on Monday, reaching $31.01. 241,269 shares of the company traded hands, compared to its average volume of 406,868. The stock has a market capitalization of $765.33 million, a P/E ratio of -9.17 and a beta of 0.44. The company's fifty day moving average price is $43.53 and its 200-day moving average price is $53.61. Disc Medicine, Inc. has a 52-week low of $25.60 and a 52-week high of $77.60.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.22). As a group, sell-side analysts forecast that Disc Medicine, Inc. will post -4.44 earnings per share for the current fiscal year.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.